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ABSTRACT
Background: Nephrocalcinosis, characterized by intratubular
and/or parenchymal deposition of calcium phosphate and
calcium oxalate crystals, is frequently seen in renal allograft
biopsies; however, the clinical consequence of this histologic
finding remains unknown. Kidney transplant recipients with
good allograft function usually demonstrate improvement in
biochemical parameters; however, persistent hyperparathy-
roidism remains prevalent in this population of patients. We
identified renal allografts with nephrocalcinosis and evaluated
the effects on renal allograft function and survival.
Methods: We conducted a single-center, retrospective review
of kidney allograft biopsies performed at our center from
December 1, 2006 to November 30, 2012. Biopsies with
nephrocalcinosis as the primary diagnosis were included in the
final analysis. Biochemical parameters at the time of biopsy
included serum creatinine, phosphate, calcium, intact parathy-
roid hormone (iPTH), 25-hydroxy vitamin D, and albumin.
Serum creatinine was measured at 1, 3, 6, and 12 months after
nephrocalcinosis was diagnosed. The use of calcimimetics,
vitamin D analogs, active vitamin D, and bisphosphonates was
also reviewed.
Results: We identified 12 patients with nephrocalcinosis as the
primary diagnosis on renal biopsy. The average age of these
patients was 52.2 – 11.9 years, and the average time since
transplantation was 2.3 – 2.7 years. The baseline serum
creatinine was 1.37 – 0.4 mg/dL before the onset of acute
kidney injury (AKI). Mean iPTH and 25-hydroxy vitamin D at the
time of AKI were 495.66 – 358.9 pg/mL and 19.9 – 13.3
ng/mL, respectively. Renal function deteriorated in all patients,
and mean serum creatinine at 12-month follow up was 2.37 –
1.3 mg/dL (P¼0.028). One patient progressed to end-stage
renal disease at the end of the study period.
Conclusion: The histologic finding of nephrocalcinosis is
associated with poor renal allograft function. Metabolic
abnormalities including hyperparathyroidism persist in renal
allograft recipients despite normal allograft function and may
be associated with the development of nephrocalcinosis in
renal transplant recipients.
INTRODUCTION
Nephrocalcinosis refers to a generalized increase
in the calcium content of the kidney and is character-
ized by intratubular or parenchymal deposition of
crystals, primarily consisting of calcium phosphate
and/or calcium oxalate. Intratubular crystal deposition
is thought to occur as a result of supersaturation,
mainly in the distal nephrons.1 Tubular obstruction
can acutely impair renal function by mechanical
blockage of tubular fluid flow. In the long term,
tubular obstruction can cause tubular atrophy, inter-
stitial inflammation, and interstitial fibrosis, leading to
chronic kidney disease (CKD).2,3
In patients with CKD, the calcium content of the
kidney usually increases as renal function deterio-
rates.4 In patients with CKD stage 5, calcium levels
can be 8-fold greater than in normal kidneys.5
Calcium oxalate crystals may be observed in the
kidneys of patients with disorders that increase the
production and excretion of oxalate. Calcium phos-
phate crystals are most commonly encountered in the
kidneys of patients with hypercalciuria such as in
patients with primary hyperparathyroidism.
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Nephrocalcinosis is also frequently observed in
renal allograft recipients. A high incidence of calcium
oxalate deposits has been reported in kidney allo-
grafts with early dysfunction.6,7 In one protocol biopsy
study from Belgium, the prevalence of calcium
phosphate crystals was 31.8% at 3 months posttrans-
plantation.8 Gwinner et al observed calcifications in
renal allografts in 26.3% of patients within the first 6
months posttransplantation.9
Despite the frequent occurrence of nephrocalci-
nosis in kidney transplant recipients, its clinical
significance remains unknown. Our study focused
on renal transplant recipients with an isolated finding
of nephrocalcinosis and attempted to identify the
long-term implication of this histologic finding on renal
allograft function and patient survival.
METHODS
We conducted a single-center, retrospective re-
view of kidney allograft biopsies performed from
December 1, 2006 to November 30, 2012. Biopsy
records were obtained by reviewing paper and
electronic medical records. Protocol biopsies are not
performed at our center, and the decision to perform
a kidney biopsy is based on the clinical judgment of
the physician. The most common indication for renal
allograft biopsy is acute allograft dysfunction. We
identified biopsies with only nephrocalcinosis as the
primary diagnosis. Biopsies with additional diagnoses
of acute rejection, acute tubular necrosis, and
recurrent or de novo glomerulonephritis were exclud-
ed.
Renal transplant biopsies were performed using a
biopsy gun with an 18-gauge needle, and at least 2
tissue cores were obtained. Tissue was preserved in
paraldehyde and Michel’s fixative; slides were rou-
tinely stained with hematoxylin and eosin (H&E),
periodic acid–Schiff (PAS), and a silver methenamine
method. H&E-stained slides of fixed and frozen tissue,
as well as the PAS and silver methenamine stain
slides, were used to look for calcification. Crystal
deposition was quantified by the number of tubules
involved.
Biochemical analysis at the time of biopsy
included review of serum creatinine, phosphate,
calcium, intact parathyroid hormone (iPTH), 25-
hydroxy vitamin D, and albumin. Serum creatinine
was also obtained at 1, 3, 6, and 12 months post
diagnosis of nephrocalcinosis. Use of calcimimetics,
vitamin D analogs, active vitamin D, and bisphospho-
nates was also analyzed.
Statistical Analysis
Means, standard deviations, and medians were
calculated for continuous variables. Frequencies and
percentages were reported for categorical variables.
Parametric paired (Student t test) and nonparametric
paired (Wilcoxon signed rank test) comparisons were
calculated to assess statistical significance from
baseline to each follow-up. Spearman correlation
coefficients were calculated to assess the degree of
linear dependence between variables of interest. A P
value <0.05 was considered statistically significant,
and all statistical analyses were performed using
Stata/IC (StataCorp LP, version 13).
RESULTS
We identified 12 patients with nephrocalcinosis as
the primary diagnosis on the biopsy. Table 1
describes baseline demographics and clinical char-
acteristics of the sample. The mean age was 52.2 –
11.9 (SD) years, 50% were male, and 75% were
African American. The most common cause for end-
stage renal disease was diabetes (58.3%), followed
by hypertension (25%). Thymoglobulin (rabbit anti-
Table 1. Baseline Characteristics of Patients (n¼12)
Variable
Mean – SD /
n (%)
Minimum-
Maximum
Age, years 52.2 – 11.9 34-75
Male 6 (50)
African American 9 (75)
White 3 (25)
Time since transplantation,
days 827.3 – 963.7 8-2,604
Time since transplantation,
years 2.3 – 2.7 0.2-7.1
Etiology of End-Stage Renal
Disease
Diabetes 7 (58.3)
Hypertension 3 (25.0)
Hepatorenal syndrome 1 (8.3)
Lupus 1 (8.3)
Predialysis 0 (0)
Type of Transplant
Deceased donor kidney
transplant 5 (41.7)
Kidney-pancreas transplant 5 (41.7)
Liver-kidney transplant 1 (8.3)
Living donor kidney
transplant 1 (8.3)
Induction Immunosuppression
Thymoglobulin (rabbit
antithymocyte globulin) 6 (50.0)
Alemtuzumab (Campath) 5 (41.7)
Steroids 1 (8.3)
Posttransplant Nephrocalcinosis
26 The Ochsner Journal
thymocyte globulin) was the induction agent in 50% of
cases, and Prograf (tacrolimus) was the calcineurin
inhibitor of choice in 11 of 12 patients. All patients
were on dialysis at the time of transplantation. The
mean time since transplantation was 2.3 – 2.7 years.
The averages of baseline biochemical profiles are
listed in Table 2. Baseline creatinine in this sample was
1.37 – 0.4 mg/dL before onset of acute kidney injury.
The means of serum phosphate and calcium were 3.7
– 1.2 mg/dL and 9.01 – 0.6 mg/dL, respectively. Mean
iPTH at the time of biopsy was 495.66 – 358.9 pg/mL
and 25-hydroxy vitamin D was 19.9 – 13.3 ng/mL.
None of the patients was taking a calcimimetic, and
only 3 of 12 patients were on active vitamin D (calcitriol)
at the time of acute kidney injury (data not shown). No
use of phosphate supplements or phosphate-contain-
ing enemas was documented.
Figure 1 and Table 3 show the comparison of
serum creatinine at baseline to each follow-up period
(1, 3, 6, and 12 months). For this paired comparison,
the sample size was reduced to 10 patients because 2
of the 12 patients were on hemodialysis at the time of
biopsy. Serum creatinine levels showed an incremen-
tal increase at 12 months compared to baseline, 2.37
vs 1.37 mg/dL, respectively, P¼0.028. Renal function
was significantly worse in all the patients at 12-month
follow-up; however, only one patient progressed to
end-stage renal disease by the end of the study
period.
When looking at the association between the
calcium phosphate product (Ca 3 PO4) and the
number of tubules with crystal deposition, a moderate
positive linear relationship was found, r¼0.60,
P¼0.037, (Figure 2), suggesting that an increase in
Ca 3 PO4 also increases the number of tubules with
crystal foci. Additional associations were tested
between Ca 3 PO4 and peak creatinine, as well as
Ca3PO4 and parathyroid hormone, but did not show
any significant results. The correlation between the
number of tubules with crystal foci and creatinine at
12 months and the number of tubules with crystal foci
and peak creatinine was also calculated but was not
statistically significant (Table 4).
DISCUSSION
The finding of nephrocalcinosis is prevalent in
renal allograft biopsies although its long-term impact
remains controversial. In one of the largest studies of
kidney transplant recipients with nephrocalcinosis, no
difference in renal function after a mean follow-up of
33 months was seen in patients with and without
calcium-phosphate deposition (1.48 – 0.83 mg/dL vs
1.45 – 0.83 mg/dL).8 In a protocol biopsy study from
Germany, nephrocalcinosis observed at 6 and 12
weeks after renal transplantation was associated with
development of chronic allograft nephropathy
(P¼0.006); however, no data on renal function or graft
survival were reported.10 In contrast, Pinheiro et al
reported significantly lower 12-year renal allograft
survival in patients with nephrocalcinosis compared
to patients without this finding (49.7% vs 74.1%,
P¼0.013).7
This histologic finding is seen more frequently in
the first year after transplantation, suggesting a
disordered mineral metabolism.8 Some animal data
suggest that alteration in mineral metabolism may
contribute to crystal deposition and renal dysfunc-
tion.11 Hypercalcemia, hypophosphatemia, and renal
phosphate wasting are common early after kidney
transplantation and are related to persistent hyper-
parathyroidism.12,13 PTH levels show a biphasic
decrease after successful transplantation, an approx-
imate 50% decrease during the first 3-6 months
followed by a more gradual decline.14 Nevertheless,
increased PTH levels persist in a substantial portion of
renal transplant recipients, despite the presence of
normal renal function.15 This condition is often referred
to as persistent (or tertiary) hyperparathyroidism. Long
Table 2. Baseline Blood Chemistries
Variable Mean – SD
Minimum-
Maximum
Creatinine, mg/dL 1.37 – 0.4
Phosphate, mg/dL 3.7 – 1.2 2.2-6.5
Calcium, mg/dL 9.01 – 0.6 8.2-10.4
Albumin, g/dL 3.21 – 0.6 2.4-4.0
Intact parathyroid hormone
at time of biopsy, pg/mL 495.66 – 358.9 80-1,254
25-hydroxy vitamin D at time
of biopsy, ng/mL 19.9 – 13.3 6-43
Figure 1. Creatinine levels for the study period.
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duration on dialysis, severe secondary hyperparathy-
roidism at the time of transplantation, or need for
calcimimetic therapy confers an increased risk for
persistent hyperparathyroidism.16 After transplantation,
suboptimal renal function, metabolic acidosis, and low
vitamin D levels may also increase PTH secretion.
Persistent hyperparathyroidism and hyperphosphato-
ninism have been shown to contribute significantly to
the occurrence of hypercalcemia and hypophospha-
temia, most likely by inducing renal phosphate wasting
(fibroblast growth factor 23 and PTH) and calcium
release from the bones (PTH).12,13,17
Our study focused on patients who developed
acute allograft dysfunction, and kidney biopsy re-
vealed nephrocalcinosis as the main histologic
finding. An overwhelming majority of the crystal
deposits were calcium phosphate; however, calcium
oxalate crystals were also observed in a few patients
(data not shown). Interestingly, the percentage of
interstitial fibrosis and tubular atrophy was mild in
most of the biopsy samples (Table 5) indicating that
renal parenchyma was well preserved in our study
sample. Despite minimal histologic abnormalities,
creatinine did not return to baseline in any of the 12
patients (1.37 – 0.4 mg/dL vs 2.37 – 1.3 mg/dL). One
patient progressed to end-stage renal disease,
requiring renal replacement therapy. In the absence
of other abnormal findings in the renal biopsy (acute
tubular necrosis, acute rejection, transplant glomeru-
lopathy, or de novo or recurrent glomerulonephritis),
nephrocalcinosis is the likely cause for progressive
renal impairment in our patients. Nephrocalcinosis in
renal allografts may not be as benign a histologic
finding as previously thought.
Although nephrocalcinosis is seen more com-
monly within the first year after transplantation, only 6
of our 12 patients were diagnosed within the first 12
months of transplantation, indicating that the meta-
bolic abnormalities persisted long after transplanta-
tion despite patients regaining near-normal renal
function. In one study, high PTH levels correlated
with inferior graft survival (P<0.05) 1 year after
transplantation in patients with calcifications.9 Persis-
tent or tertiary hyperparathyroidism was also preva-
lent in our patient sample; however, hypercalcemia
and hypophosphatemia were not observed unlike in
previous studies.12,13,17 Hypercalcemia and hypo-
phosphatemia have been independently associated
with nephrocalcinosis in renal transplant recipients.13
Our study also showed a moderately positive linear
relationship between Ca 3 PO4 and the number of
tubules with crystal foci. The significance of this
finding remains unknown because we know that in
addition to urinary calcium and phosphate load,
urinary pH and the concentration of inhibitors such
as citrate, magnesium, pyrophosphate, and urinary
proteins determine precipitation of microcrystals.18,19
Unfortunately, urinary indices were only performed in
Table 3. Comparison of Creatinine Level at Follow-Up Periods
Variable Baseline 1 Month (P value) 3 Months (P value) 6 Months (P value) 12 Months (P value)
Creatinine, mg/dL 1.37 – 0.40 2.42 – 0.86 (0.012) 2.19 – 0.58 (0.001) 2.46 – 0.86 (0.002) 2.37 – 1.30 (0.028)
Note: In this parametric paired (Student t test) comparison, n was reduced to 10 because 2 patients who were on hemodialysis did not have recorded
baseline creatinine levels. Values are reported as mean – SD.
Figure 2. Correlation between calcium phosphate product
(Ca3 PO4) and the number of tubules with crystal foci.
Table 4. Calcium Phosphate Product (Ca 3 PO4) and
Correlations
Variable ra P value
Ca 3 PO4 and number of tubules
with crystal foci 0.603 0.037
Ca 3 PO4 and intact parathyroid
hormone at time of acute kidney
injury 0.419 0.174
Ca 3 PO4 and peak creatinine at
acute kidney injury 0.490 0.149
Number of tubules with crystal
foci and peak creatinine 0.184 0.609
Number of tubules with crystal
foci and creatinine at 12 months 0.245 0.468
aSpearman correlation coefficient.
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4 of 12 patients; hypocitraturia was seen in all 4
patients, but hypercalciuria was not observed.
Our study has several limitations. It is strictly an
observational study with a small sample size, rela-
tively short follow-up, and no control group for
comparison. Also, follow-up biopsies to document
resolution or progression of nephrocalcinosis were
not performed in all patients.
CONCLUSION
Our study points to the importance of identifying
patients with persistent or tertiary hyperparathyroid-
ism because these patients may be at risk for
developing nephrocalcinosis. Aggressive treatment
of hyperparathyroidism in the pretransplant period,
whether by the use of calcimimetics or surgery, may
be pivotal. Prospective studies are needed to further
investigate this finding.
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Table 5. Biopsy Characteristics
Variable Mean – SD Minimum-Maximum
Number of tubules with
crystal deposits 18.08 – 13.4 4-48
Interstitial fibrosis and
tubular atrophy, % of
sample 22.91 – 26.1 5-100
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